Authors' Response to Peer-Review Reports https://med.jmirx.org/2023/1/e50515
Published Article https://med.jmirx.org/2023/1/e29587
This is a peer-review report submitted for the paper “Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study.”
Review Round 1
This article is a pilot study  that was conducted to determine the prevalence, patterns, and dynamics of COVID-19 and the risk factors for contracting the disease in Niger State from June 26 to 30, 2020.
This study is a cross-sectional study and uses a clustered, stratified random sampling method. Only 185 participants were included in the study. The sample size is small.
The seroprevalence of COVID-19 was found to be 25.4% and 2.16% for the positive IgG and IgM, respectively. These seroprevalence results mean that herd immunity to COVID-19 has yet to be achieved, and the population is still susceptible to more infection and transmission of the virus.
- Samples were taken randomly from 185 participants for COVID-19 IgG and IgM rapid tests and questionnaires. Information on the number of patients included in the different sampling points is missing. Have serology results been confirmed by other techniques?
- The results are expressed as a percentage; it would be interesting to have the data on the number of samples or the number of patients.How many participants tested positive for only IgG and for both IgG and IgM?
- Bibliographic references are not formatted in the correct format.
- Page 1: explain “NCDC”
- Page 5: italicize Chlamydia pneumoniae, Mycoplasma pneumoniae, Treponema pallidum
- Page 9: add percent majority (61.62%)
- Page 11: explain “ATM”
- Page 14: replace igM with IgG, “while the Kit detecting only IgM means that...”
- Page 19: explain “PPE”
Review Round 2
This paper describes the seroprevalence of COVID-19 in Niger State. This is a pilot study.
Despite the authors’ efforts to respond specifically to comments, some points are still missing.
- Please include more quantitative results in the abstract (odds ratio with CIs).
- The relative results (percentage) are not well presented. Mostly, if n is less than 100, do not use decimal points in your percentages. We need to review the data in Table 2.
- The 95% CIs for the odds ratios are missing in Table 2.
- The SARS-CoV-2 script must be homogenized throughout the manuscript.
- The meaning of the a is missing in Table 2.
- Almost all the information in Table 2 is already in the text.
- Page 3: replace “COVI-19” with “COVID-19” and remove “Coronavirus disease 2019”
- The SARS-CoV-2 script must be homogenized throughout the manuscript
- How were the kits validated by polymerase chain reaction?
- Page 17: explain “ATMs” in the paper
Conflicts of Interest
- Majiya H, Aliyu-Paiko M, Balogu VT, Musa DA, Salihu IM, Kawu AA, et al. Seroprevalence of SARS-CoV-2 in Niger State: pilot cross-sectional study. JMIRx Med 2023;4:e29587 [CrossRef]
Edited by Edward Meinert; This is a non–peer-reviewed article. submitted 29.06.23; accepted 29.06.23; published 17.10.23Copyright
© Nadège Bourgeois-Nicolaos. Originally published in JMIRx Med (https://med.jmirx.org), 17.10.2023.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIRx Med, is properly cited. The complete bibliographic information, a link to the original publication on https://med.jmirx.org/, as well as this copyright and license information must be included.